HK2 and cancer: Moreover, MAO inhibitors impaired cancer cell glucose metabolism by decreasing the expression of glucose transporter 1 (GLUT1) and hexokinase 2 (HK2) with reduced glycolysis and oxidative phosphorylation in conjunction with pyruvate depletion [69].